China NMPA approves Sciwind’s GLP-1 injection for diabetes
Sciwind Biosciences Co. Ltd. said Jan. 30 it won Chinese approval for self-developed glucagon-like peptide-1 (GLP-1) receptor agonist, ecnoglutide (Xianyida), to treat adults with type 2 diabetes.
Pfizer’s Metsera GLP-1 hits mark for once-monthly dosing
Nearly three months after winning a contentious bid to buy obesity drugmaker Metsera Inc. for $10 billion, Pfizer Inc. reported its first statistically significant top-line data of the acquired lead, ultra-long-acting glucagon-like peptide-1 (GLP-1) receptor agonist, showing a mean placebo-adjusted weight loss of up to 12.3% at 28 weeks, as well as competitive tolerability.
GLP-1 drugs tied to lower-calorie, lower-sugar food purchases
Researchers at Steno Diabetes Center Copenhagen reported that starting a GLP-1 receptor agonist (GLP-1RA) coincided with slightly healthier supermarket purchases. Grocery purchases from GLP-1RA users in Denmark contained modestly fewer calories and sugars and slightly more protein per 100 g of food after treatment began than before.
Hormone Therapy Boosts Weight Loss on Tirzepatide for Postmenopausal Women
TUESDAY, Feb. 3, 2026 — Postmenopausal women who used hormone therapy lost significantly more weight while taking tirzepatide than women only taking tirzepatide, according to a study published online Jan. 22 in The Lancet Obstetrics, Gynaecology…
Novo’s Next-Gen Obesity Drug Beats Wegovy on Blood Sugar Control in Phase III
While CagriSema bested Novo Nordisk’s Wegovy on blood sugar control in a late-stage trial, the next-gen weight loss drug still has not met the pharma’s 25% weight loss goal.
Updated: Do Pfizer’s monthly GLP-1 data justify Metsera’s $10B price tag?
Pfizer said Tuesday that the monthly injection that was one of the cornerstones of its $10 billion buyout of Metsera allowed obesity patients to lose up to 10.5% of their weight, on …
GLP-1 Pill Cut Heart Failure Events in Some Diabetes Patients
(MedPage Today) — Oral semaglutide (Rybelsus) protected against heart failure events in type 2 diabetes patients with a history of heart failure and either atherosclerotic cardiovascular disease, chronic kidney disease, or both, according to findings…
New CagriSema data show improvement over semaglutide
Novo Nordisk’s next-gen metabolic drug CagriSema performed better than the blockbuster semaglutide at reducing blood sugar and weight in patients with type 2 diabetes.
That was the topline result from the latest Phase 3 readout …
What is ‘food noise’? UK surgeon explains why people with obesity are more reactive to food; shares 5 ways to curb it
“Food noise” is a real thing where some brains experience heightened reward sensitivity associated with food. Dr Rajan explains how GLP-1 treatment can help.
GLP-1 Warning Over Link to Fatal Events; DOJ Sues Med School; Genes and Longevity
(MedPage Today) — Note that some links may require registration or subscription.
The United Kingdom’s Medicines and Healthcare Products Regulatory Agency strengthened its warnings on GLP-1 receptor agonists and dual GLP-1/GIP agonists to include…